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Abstract
Background
Perioperative chemotherapy increases the overall and progression-free survival of patients
suffering from resectable adenocarcinomas of the lower esophagus, gastroesophageal
junction and stomach (GEC). Comparing different chemotherapy regimens platin-based
protocols with 5-fluorouracil (5-FU)/calcium folinate (CF) or oral fluoropyrimidines were fa-
vorable in terms of efficacy and side-effects. However, there is no consensus which regi-
men is the most efficacious.
Methods
42 consecutive patients with resectable GEC (UICC II and III) were treated with 3 pre- and
postoperative chemotherapy cycles each consisting of epirubicin, oxaliplatin and capecita-
bine (EOX). We analyzed the overall survival, progression-free survival and toxicity retro-
spectively in comparison to published data.
Results
The median overall survival in our cohort was 29 months and the progression-free survival
was 17 months. The most frequent grade 3 and 4 toxicities during preoperative chemothera-
py were diarrhea (16.7%), leukocytopenia (9.5%) and nausea (9.5%); overall 38.1% of our
patients suffered from grade 3 or 4 toxicity. Surgery was carried out in 83% of our patients,
69% of those achieved R0 resection.
Conclusion
Comparing our data with the results of previously published randomized trials EOX is at
least non-inferior with regard to overall survival, progression-free survival and toxicity. In
conclusion, EOX is an appropriate perioperative therapy for patients with resectable GEC.
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Introduction
Gastroesophageal adenocarcinomas of the lower esophagus, gastroesophageal junction and
stomach (GEC) belong to the most common malignancies. The incidence of gastroesophageal
junction and lower esophagus adenocarcinoma increases whereas the incidence of stomach
cancer decreases [1,2]. Stomach cancer is still the fourth most common malignancy worldwide
responsible for 738,000 deaths annually [3].
In early stages endoscopic mucosal resection, endoscopic submucosal dissection or minimal
invasive surgery can be a curative therapy, but at the time of diagnosis most patients suffer from
advanced or metastatic disease. Surgery is the favored treatment also for locally advanced cancer
[4], however most patients have a relapse. 5-year-survival rates are about 10% for esophageal
and about 21% for gastric cancer [5]. In advanced cancer neoadjuvant chemotherapy was added
to reduce the tumor bulk and to eradicate micrometastasis [6]. In a meta-analysis neoadjuvant
chemotherapy had a 2-year absolute survival benefit of 7% [7]. The limitation of this approach
could be an insufficient eradication of micrometastasis, thus adjuvant chemotherapy was added
[8]. The advantage of perioperative chemotherapy was documented in large scale randomized
trials comparing different chemotherapy protocols [8]. The absolute 5-year-survival rate benefit
was in the range of 10–15% with a hazard ratio of 0.6–0.8, regardless of the perioperative ap-
proach. Therefore different perioperative chemotherapy regimens are still used [8].
The MAGIC study by Cunningham et al. compared the effect of surgery alone with periop-
erative epirubicin, cisplatin and 5-FU/CF (ECF) chemotherapy in 503 patients suffering from
resectable GEC [9]. Perioperative chemotherapy with ECF resulted in cancer regression and a
significant extended progression-free and overall survival [9]. This approach was confirmed by
another trial [10].
The REAL-2 study compared the efficacy of different perioperative chemotherapy protocols
(ECF, ECX (epirubicin, cisplatin, capecitabine), EOF (epirubicin, oxaliplatin, 5-FU/CF), EOX
(epirubicin, oxaliplatin, capecitabine)) in overall 1002 patients suffering from locally advanced
(inoperable) or metastatic gastroesophageal cancer [11]. The longest survival time was observed
for EOX treated patients. Overall, the authors concluded that EOX was as effective as ECF in pa-
tients with previously untreated GEC. Further clinical trials confirmed the high efficacy of the
EOX protocol [12].
On the basis of these published studies we started to treat patients suffering from histologi-
cally proven resectable GEC in the perioperative setting routinely with a modified EOX proto-
col. Here we report a retrospective analysis of all our patients treated between January 2008
and September 2013 with regard to treatment efficacy and safety.
Methods
Patients
42 consecutive patients suffering from resectable gastroesophageal adenocarcinoma and fit for
chemotherapy and radical surgery as determined by an interdisciplinary tumor board were re-
cruited for EOX treatment. The pretreatment tumor staging comprised upper GI-tract endos-
copy, radial endoscopic ultrasonography, and abdomen and thorax computed tomography
according to the ESMO guidelines for esophageal and gastric cancer [13] [14]. Written in-
formed consent was obligatory.
Main contraindications for EOX therapy were ECOG status 2 (Eastern Cooperative On-
cology Group performance status), instable cardiac disease, hemodynamic relevant arrhyth-
mia, renal impairment according to the drug product label (creatinine clearance<30ml/min)
and inadequate cellular blood counts.
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After confirmation by the Ethic Comitee at Aerztekammer Westfalen-Lippe (AEKWL) Ger-
many, patient records were anonymized and de-identified prior to analysis.
Treatment
The treatment protocol consisted of 3 preoperative and 3 postoperative EOX cycles each in in-
tervals of 21 days. Each cycle consisted of epirubicin (50 mg/m2) by short infusion over 30 min-
utes followed by oxaliplatin (130 mg/m2) infused over 120 minutes on day 1. Capecitabine was
given orally from day 1 to day 14 bidaily at a dose of 1250mg/m2 (2500 mg/m2/d). Infusions
were administered by an intravenous port. Routinely dexamethasone, granisetron, clemastin
and fosaprepitant were given for antiemetic prophylaxis, loperamide for diarrhea, and thrice
daily 10% urea topically to prevent hand-and-foot-syndrome.
Clinical assessment was conducted by an experienced oncologist prior to chemotherapy. A
complete cellular blood count, serum electrolytes, and liver and kidney function were deter-
mined. Relevant peripheral cytopenia resulted in dose adjustment; the capecitabine dose was
reduced if severe diarrhea occurred or replaced by 5-FU/CF in an equivalent dose if patients
were suffering from clinical relevant dysphagia.
Chemotherapy associated intolerance symptoms were documented according to the National
Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0. Con-
tinuation of the therapy regimen was individually discussed with patients dependent on subjec-
tive and objective tolerability.
Therapy efficacy was evaluated by upper GI-tract endoscopy, radial endoscopic ultrasonog-
raphy, CT or PET-CT preoperatively. The radiologic response was calculated according to
RECIST criteria [15]. In case of tumor regression the surgical intervention was conducted 3–6
weeks after the third chemotherapy cycle. Chemotherapy continuation or premature surgery
was individually discussed with patients in the case of stable disease. Disease progression re-
sulted in chemotherapy cessation and accelerated surgical intervention.
The procedure was determined according to the tumor site by the surgeon. Staging was sup-
plemented by histopathological evaluation of the surgical specimen, the histopathological re-
gression due to chemotherapy was documented according to the Baldus et al. classification
system (Grade 1–4, 2004) [16]. The downstaging rate was calculated comparing the initial clin-
ical with the pathological tumor and nodal state.
Postoperative chemotherapy was initiated 6 to 12 weeks after surgery with 3 cycles of EOX
in 3 weekly intervals.
Follow-up care frequency was 3 months during the first follow-up year, 6 months during
the second year, then once a year. Clinical inspection, upper GI-tract endoscopy, CT-scan ac-
cording to tumor site and abdominal ultrasound were performed routinely, CA 72–4 and CEA
were analyzed in patients with elevated values at the time of diagnosis. Our database was closed
at 26th of March 2014.
Statistical Analysis
The primary objective of this evaluation was the calculation of progression-free (PFS) and
overall survival (OS) of patients treated by pre- and postoperative EOX chemotherapy in com-
parison with data from the literature. Overall survival (OS) is the time between the initial diag-
nosis and the date of death from any cause or the last day of follow-up. Progression-free
survival (PFS) is the time from diagnosis to the date of relapse, disease progression, or the last
day of follow-up. Kaplan-Meier curves were calculated with IBM SPSS Statistics 22.
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Further outreads of this analysis were the operability after chemotherapy with the intent of
a complete resection (R0), treatment toxicity, pathological response rate, down-staging by che-
motherapy, and Baldus regression status.
Prognostic factors (gender, tumor size, histological tumor grading, histopathological nodal
state, and tolerability of chemotherapy) were analyzed by the use of Kaplan-Meier log-rank test
and Cox univariate regression analysis. The values of statistically significant factors were evalu-
ated in a multivariate stepwise forward Cox regression model.
Results
Characteristics of patients
The characteristics of our 42 patients are summarized in Table 1. 40 patients suffered from can-
cer of stage group UICC II and UICC III. 1 patient was included despite diagnosis of a resectable
Table 1. Pretherapeutical patient’s and tumor characteristics, and tumor localization.
Variable Value
Age at diagnosis: range 35.7–82.1 years
Median (years) 61.55
Gender
Male (n) 36 (85.7%)
Female (n) 6 (14.3%)
Performance status (ECOG scale)
0 26
1 16
Tumor localization
Esophagus (n) 3
Junction AEG 1–3 (n) 29
AEG 1 17
AEG 2 10
AEG 3 2
Stomach (n) 10
Clinical T stage
T 1 (n) 0
T 2 (n) 8
T 3 (n) 30
T 4 (n) 4
Clinical UICC stage
UICC I 1 (2.4%)
UICC II 11 (26.2%)
UICC III 29 (69.0%)
UICC IV 1 (2.4%)
Maximum tumor diameter (n = 38)
0.0–3.9cm 10 (26.3%)
4.0–7.9cm 24 (63.2%)
8.0–11.9cm 4 (10.5%)
Grading
G1 3 (7.1%)
G2 11 (26.2%)
G3 28 (66.7%)
doi:10.1371/journal.pone.0122974.t001
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solitary liver metastasis (UICC IV) and 1 patient with UICC stage Ib. The majority of our pa-
tients were male. The median age was 61.5 years. None had a previous chemotherapy or concur-
rent malignancy. All patients had a good performance status according to the ECOG scale (26
patients ECOG 0 and 16 patients ECOG 1).
Treatment
Preoperative chemotherapy. The median time between diagnosis and chemotherapy was
32 days (standard deviation (SD) 16.6 days) with a minimum of 14 and a maximum of 105 days.
The complete preoperative regimen (3 chemotherapy cycles) was administrated to 31 pa-
tients; 7 patients had 2 and 4 patients 1 cycle. Reasons for cessation of preoperative chemothera-
py were: toxic effects in 10 patients (severe intestinal side effects (n = 3), severe hematotoxicity
(n = 2), severe stomatitis (n = 1), hand-foot syndrome (n = 1), cardiac ischemia (n = 1), acute
renal failure (n = 1) and laryngopharyngeal spasm (n = 1)).
Surgical intervention. 2 patients died during the preoperative phase (1 progress related
death and 1 death after completion of 3 preoperative cycles), in 5 patients surgery was cancelled
(in 3 due to progress, 2 patients refused surgery). 35 (83.3%) of the initial 42 patients had a sur-
gical procedure (with the purpose of gastrectomy, transhiatal extended cardia resection or distal
esophagectomy): R0 resection was documented in 24/35 (68.6%), R1 resection in 6 (17.1%), R2
resection in 2 patients (5.7%), of these 1 patient underwent a palliative R2-gastrectomy with
lymphadenectomia and the other a tumor bulk reduction with reconstruction of the intestinal
passage. In 2 patients the resection was stated as RX (5.7%). In 1 patient surgery was determined
after explorative laparotomy. The median time between diagnosis and surgery was 121 days (SD
24.6 days), and between preoperative chemotherapy and surgery 32 days (SD 14.7 days).
Postoperative chemotherapy. Postoperative chemotherapy was restarted in 14 patients
(40%) in median 47.5 (SD 23.2 days) after the procedure. A second postoperative cycle could
be administered in 11 and a third in 10 patients.
Chemotherapy restart was precluded by intolerable previous toxicity or treatment inefficacy
in 9 patients and patients request or postoperative complications in 12 patients. The subsequent
treatment was determined after discussion in our tumor review board on an individual base.
Chemotherapy adverse effects. The EOX associated adverse effects during the pre- and
postsurgical phases are summarized in Table 2. Grade 3 or 4 toxicity was observed in 16 pa-
tients (38.1%) during preoperative chemotherapy with need for inpatient admission in 16 indi-
viduals. Postoperatively grade 3 or 4 toxicity was observed in 4 patients (28.6%). A reduction of
chemotherapeutic agents dose was documented in 31 therapy cycles applied to 12 patients.
Efficacy
Preoperative chemotherapy efficacy and response rates are summarized in Table 3. By radio-
logical evaluation 38 out of 40 patients (95%) with at least 1 cycle had a partial response
(47.5%) or stable disease (47.5%) prior to surgery. Comparing the pathological stage with the
baseline clinical stage a TNM downstaging was found in 18/35 patients (51.4%). A major re-
sponse to chemotherapy defined as histopathological regression grade 3+4 (less than 10% re-
sidual tumor) was found in 10 patients (30.3%), of these 1 had a complete regression; grade 2
regression was documented in 8 patients (24.2%), and grade 1 regression in 15 (45.5%).
The median follow-up period was 19 months (range 1–49 months). 1 patient was lost to
follow-up. 24 patients (57.1%) had disease progression, in median after 10 months (range 1–30
months). During the evaluation period 20 patients died (48%): 16 cancer related, 1 during post-
surgical phase, 1 prior to surgery with unknown cause of death and 2 during follow-up (1 car-
diac disease, 1 unknown cause).
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For the complete patient group the median PFS was 17 months (95%CI 11.6–22.4) and the
median OS was 29 months (95%CI 13.3–44.7). Kaplan-Meier curves of PFS and OS are given
in Fig 1. For patients with surgical intervention the median PFS was 18 months (95%CI 11.9–
24.1, mean 24.8) and the median OS 34 months (95%CI 11.7–56.3, mean 33.2). In Fig 2 the
Kaplan-Meier curves of PFS and OS are given according to the postsurgical UICC stages. The
PFS was significantly higher for UICC stage 0, I and II each compared with the PFS of patients
with the higher stages. The PFS for patients was not significantly different between UICC stage
III and IV. Comparing the OS of patients according to UICC stages differences were
not significant.
In the univariate log-rank test a negative histopathological nodal status ypN (p = 0.012), a
high number of preoperative (p = 0.042) and at least one postoperative chemotherapy cycle(s)
(p = 0.011), R0 resection (p = 0.013), downstaging by chemotherapy (p = 0.006), and complete
or nearly complete regression of the tumor after preoperative chemotherapy (Baldus regression
grade 3 and 4) (p = 0.015) were significantly related to a longer PFS. Significant positive prog-
nostic factors for OS were 3 preoperative (p = 0.031) and at least 1 postoperative chemotherapy
Table 3. Response rates to preoperative EOX chemotherapy.
Variable N (%)
Radiologic response after preoperative EOX Partial response 19/42 (45.2)
Stable disease 19/42 (45.2)
Progressive disease 2/42 (4.8)
Not done 2/42 (4.8)
Downstaging after surgery Yes 18/35 (51.4)
No 17/35 (48.6)
Histopathological regression Baldus Grade 1 (>50% residual tumor) 15/33 (45.5)
Grade 2 (10–50% residual tumor) 8/33 (24.2)
Grade 3 (<10% residual tumor) 9/33 (27.3)
Grade 4 (complete regression) 1/33 (3.0)
doi:10.1371/journal.pone.0122974.t003
Table 2. Chemotherapy related adverse effects during preoperative and postoperative treatment phase.
Adverse effect Preoperative n (%) Postoperative n
Grade 0 Grade 1 or 2 Grade 3 or 4 Grade 0 Grade 1 or 2 Grade 3 or 4
Hematologic
Anemia 30 (71.4%) 12 (28.6%) 0 9 5
Thrombocytopenia 36 (85.7%) 5 (11.9%) 1 (2.4%) 12 2
Leukocytopenia 19 (45.2%) 19 (45.2%) 4 (9.5%) 7 5 2
Non haematologic
Nausea 10 (23.8%) 28 (66.7%) 4 (9.5%) 0 14 0
Vomiting 30 (71.4%) 12 (28.6%) 0 6 8 0
Diarrhea 25 (59.5%) 10 (23.8%) 7 (16.7%) 5 8 1
Hand-foot syndrome 40 (95.2%) 2 (4.8%) 14 0 0
Neurologic Effects 35 (83.3%) 7 (16.7%) 0 11 1 2
Thrombosis 39 (92.9%) 0 3 (7.1%) 13 0 1
Stomatitis 40 (95.2%) 1 (2.4%) 1 (2.4%) 14 0 0
Cardiac Ischemia 39 (92.9%) 0 3 (7.1%) 14 0 0
doi:10.1371/journal.pone.0122974.t002
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Fig 1. Kaplan-Meier plots of progression-free survival (a) and overall survival (b).
doi:10.1371/journal.pone.0122974.g001
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Fig 2. Kaplan-Meier plots of PFS (a) and OS (b) according to postsurgical UICC stages.
doi:10.1371/journal.pone.0122974.g002
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cycle (p = 0.042), chemotherapy hematotoxicity (p = 0.028) and the ability of surgical interven-
tion (p<0.001).
In the multivariate Cox regression analysis only the lymph node status at the time of surgi-
cal intervention had a significant impact on PFS, the statistical significance of all other factors
were lost in the multivariate analysis.
Discussion and Conclusions
Here we report our experience with perioperative EOX chemotherapy in a treatment regimen
for patients suffering from principally resectable advanced gastroesophageal adenocarcinomas.
Compared to data in the literature we find that this approach was highly efficacious, and toxici-
ty was well tolerable. Considering those patients of our study having undergone surgery the
median PFS was 18 months and the median OS 34 months. As a result of the small number of
patients the OS did not correlate with postsurgical UICC stages as expected, but the PFS was
longer in UICC stage 0, I and II patients.
The efficacy of different chemotherapy protocols was evaluated in the REAL-2 study in pal-
liative patients suffering from inoperable or metastatic GEC [11]. EOX was favorable due to
the toxicity profile, the differences between the median survival times were not statistically sig-
nificant (9.9 months for ECF, 9.9 months for ECX, 9.3 months for EOF, and 11.2 months for
EOX). In a NICE statement from 28th July 2010 capecitabine has been recommended in com-
bination with platinum-based chemotherapy protocols as a first-line treatment of inoperable
advanced gastric cancer [17]. A clear recommendation for the perioperative situation does not
exist so far.
The MAGIC study had demonstrated a better outcome of perioperative ECF chemotherapy
in comparison to surgery alone for patients suffering from principally resectable GEC with re-
gard to PFS (hazard ratio 0.66) and OS (hazard ratio 0.75) [9]. The five-year survival rate after
surgery alone was 23% but 36.3% for patients with additional perioperative chemotherapy. We
replaced cisplatin by oxaliplatin and 5-FU/CF by capecitabine on the base of the REAL-2 study
and modified the chemotherapy protocol; we administered capecitabine in a higher dose (2500
mg/m2) over a shorter period (14 days). Patient characteristics (age, gender, tumor stage) in
the MAGIC study and our patient collective were comparable. The difference in the median
follow-up period (49 months in the MAGIC study for patients in the perioperative chemother-
apy group, and 19 months in our patients collective) represents a limitation for comparability.
According to the presented MAGIC trial data it could be estimated that the median PFS was
about 18 months and the median OS about 25 months for the patients in the perioperative
chemotherapy group.
Our data give some evidence that the number of chemotherapy cycles is related to longer
OS. Patients treated with a minimum of one post-operative chemotherapy cycle had a trend for
longer OS with a mean of 38.1 months versus 28.3 month (p = 0.042) for patients without
postoperative chemotherapy.
In the literature the toxicity data for capecitabine were not inferior to 5-FU/CF although
there was evidence of some differences in adverse event profiles [17]. In a clinical trial on 224
patients suffering from resectable GEC patients were treated with 2 or 3 preoperative and 3 or
4 cycles postoperative cycles consisting of cisplatin and 5-FU/CF [10]. Grade 3 or 4 toxicity
was reported in 41 patients (38%) due to preoperative chemotherapy, in our patient collective
this were 16 out of 42 patients (38.1%). Hematotoxicity was relatively mild in our patients with
grade 3 and 4 leukocytopenia in 9.5%, thrombocytopenia in 2.4%, severe anemia was not ob-
served. Grade 3 or 4 hematotoxicity during postoperative chemotherapy was only observed in
2/14 patients, both suffered from leukocytopenia. We found that the incidence of grade 3 and 4
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toxicity due to the combination of 3 chemotherapeutic agents was comparable with a regimen
consisting of cisplatin and 5-FU/CF [10].
To date all chemotherapy protocols for patients suffering from advanced GEC are based on
5-FU/CF or oral fluoropyrimdine in combination with either cisplatin or oxaliplatin. The addi-
tion of epirubicin as third agent has been shown to be more effective associated with an accept-
able increase of toxicity. With all the limitations of a retrospective analysis our data support the
hypothesis that it is safe to modify the original MAGIC regimen by replacement of cisplatin
with oxaliplatin and the 21-day infusion of 5-FU/CF with capecitabine in the perioperative set-
ting without losing efficacy.
Recently, the efficacy of other treatment protocols for potentially curable GEC has been
published. The addition of docetaxel instead of epirubicin is another approach in preoperative
and perioperative regimens [18–20]. The efficacy of neoadjuvant chemoradiotherapy in the
preoperative setting has been approved, representing an alternative approach to chemotherapy
alone [21].
The debate on the optimal chemotherapy regimen in this setting is not closed, although it is
unlikely that there will be a head to head comparison of different protocols. The introduction
of new substances in treatment protocols for patients suffering from resectable GEC such as
trastuzumab which already has been approved for the metastatic situation in Her2/NEU posi-
tive GEC is currently under evaluation. New protocols combining classical chemotherapy and
biological agents have been promising in early studies, but often failed in randomized phase III
trials. One example is the combination of EOX and panitumumab which resulted in an unac-
ceptable level of toxicity and was less efficacious compared with EOX [22,23]. However, the
EOX regimen is one standard regimen in first line therapy for metastatic GEC and we think
our data supports its use also in the perioperative setting.
Finally, there is still an unmet need for further prospective trials to define multimodality
treatment protocols with better efficacy and tolerability.
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